Log in to search using one of your social media accounts:

 

Efficacy and safety maintained in patients who switched from Humira ® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24. (Source: World Pharma News)
Source: World Pharma News - November 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

One year data showing CYLTEZO is equivalent to HUMIRA
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 6, 2017 Category: Research Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise
(Reuters) - AbbVie Inc on Friday said it expects its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie tops estimates, predicts Humira sales to hit $21bn by 2020
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 27, 2017 Category: Pharmaceuticals Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020
(Reuters) - AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Asacol vs. Humira
Title: Asacol vs. HumiraCategory: MedicationsCreated: 10/6/2017 12:00:00 AMLast Editorial Review: 10/6/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 6, 2017 Category: Drugs & Pharmacology Source Type: news

Humira Again Top-Selling Drug In U.S.
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 4, 2017 Category: General Medicine Source Type: news

Humira Again Top-Selling Drug In U.S.
Title: Humira Again Top-Selling Drug In U.S.Category: Health NewsCreated: 10/4/2017 12:00:00 AMLast Editorial Review: 10/4/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 4, 2017 Category: Rheumatology Source Type: news

Humira Again Top-Selling Drug In U.S.
Popular anti-inflammatory leads list of top-selling drugs for fifth straight year. (Source: WebMD Health)
Source: WebMD Health - October 3, 2017 Category: Consumer Health News Source Type: news

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023
(Reuters) - Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie makes peace with Amgen over Humira patents
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 28, 2017 Category: Pharmaceuticals Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates Amgen Acknowledges Validity of AbbVie's Extensive Intellectual Property Portfolio for... Biopharmaceuticals, Generics, Litigation, Licensing AbbVie, Amgen, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that it has reached a global settlement with AbbVie to resolve all ... Biopharmaceuticals, Generics, Litigation, Licensing Amgen, AbbVie, AMGEVITA, AMJEVITA, Humira, adalimumab, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA ™
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, a...
Source: Amgen News Release - September 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

RA Activity Stable After Prolonging Adalimumab Interval RA Activity Stable After Prolonging Adalimumab Interval
Reducing the frequency of adalimumab did not worsen disease activity or function in patients with rheumatoid arthritis and may safely lower treatment costs and risks for adverse events, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

Positive CHMP opinion for adalimumab biosimilar CYLTEZO
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 14, 2017 Category: Research Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira ®
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: (Source: World Pharma News)
Source: World Pharma News - September 4, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 29, 2017 Category: Drugs & Pharmacology Source Type: news

Adalimumab biosimilar CYLTEZO receives FDA approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 28, 2017 Category: Research Source Type: news

FDA Approves Second Humira Biosimilar, Cyltezo FDA Approves Second Humira Biosimilar, Cyltezo
Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Second Humira Biosimilar Approved
(MedPage Today) -- FDA announces approval of Cyltezo (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

Samsung, Biogen version of AbbVie's Humira approved in Europe
(Reuters) - Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - August 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Finger prick test allows patients taking autoimmune drug to avoid blood draws
(Wiley) A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira
Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira. (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

AbbVie to remain cautious on drug pricing, shares fall
(Reuters) - AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on Humira, Imbruvica demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on robust Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit rises 19 percent on Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported an 18.9 percent rise in quarterly profit on Friday on strong demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Interchangeability study on BI 695501 vs Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 26, 2017 Category: Research Source Type: news

CHMP Recommends Imraldi, a Biosimilar to Humira CHMP Recommends Imraldi, a Biosimilar to Humira
The CHMP has recommended Imraldi, a biosimilar to Humira.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

EU backs second biosimilar copy of Humira, world's top drug
FRANKFURT (Reuters) - European regulators have recommended approval of a second copy of AbbVie's rheumatoid arthritis drug Humira, the world's top-selling medicine, in a further boost for so-called biosimilars in the region. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Biosimilar for Adalimumab in Rheumatoid Arthritis New Biosimilar for Adalimumab in Rheumatoid Arthritis
A large multinational study compares the efficacy and safety of FKB327 biosimilar to adalimumab in active rheumatoid arthritis. But antidrug antibody levels raise questions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA ®
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid. (Source: World Pharma News)
Source: World Pharma News - June 15, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

biosimilar candidate shows clinical equivalence Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 14, 2017 Category: Research Source Type: news

AbbVie shares dip after it loses round in Humira patent fight
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 16, 2017 Category: Pharmaceuticals Source Type: news

Adalimumab Effective in Children and Adolescents With Severe Psoriasis Adalimumab Effective in Children and Adolescents With Severe Psoriasis
Adalimumab offers benefits over methotrexate in children and adolescents with severe chronic plaque psoriasis, according to a phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

JIA Uveitis Control Improved With Adalimumab + MTX JIA Uveitis Control Improved With Adalimumab + MTX
Adding adalimumab to MTX for treatment-resistant uveitis was associated with juvenile idiopathic arthritis improved disease control and enabled many patients to reduce or stop topical glucocorticoids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

AbbVie profit beats on Humira demand; cheers Trump tax plan
(Reuters) - AbbVie Inc reported a bigger-than-expected quarterly profit, lifted by demand for its flagship drug, Humira, and called President Donald Trump's tax plan "encouraging". (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Clinical trial discovers a new way to prevent children with arthritis and eye disease losing their sight
This study demonstrates the benefit of adalimumab in children with uveitis. This is the first randomised trial of its kind worldwide and the results will have a major impact in children with uveitis all around the world."Finding the best way of caring for children with arthritis and uveitisProfessor Beresford from University of Liverpool and Alder Hey Children’s NHS Foundation Trust said: "This landmark trial has demonstrated the commitment and leadership of colleagues across the UK in working closely with patients and parents in tackling a key priority of finding the very best way of caring for children wi...
Source: Arthritis Research UK - April 26, 2017 Category: Rheumatology Source Type: news

What Causes Uveitis?
Discussion Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and> 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increase...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2017 Category: Drugs & Pharmacology Source Type: news

Fingernail Psoriasis Data Added to Humira Prescribing Info Fingernail Psoriasis Data Added to Humira Prescribing Info
The FDA has approved the addition of moderate to severe fingernail psoriasis data to the Humira prescribing information for those with moderate to severe chronic plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 30, 2017 Category: Dermatology Tags: Dermatology News Alert Source Type: news

U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail ps... Biopharmaceuticals, FDA AbbVie, HUMIRA, adalimumab, Fingernail Psoriasis, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2017 Category: Pharmaceuticals Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-s...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

AS: TNF Inhibitors Differ in Uveitis Risk (CME/CE)
(MedPage Today) -- Adalimumab and infliximab have lowest risk (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 18, 2017 Category: Geriatrics Source Type: news